Browsing Tag
respiratory syncytial virus
9 posts
GSK wins FDA approval to extend Arexvy RSV vaccine to at-risk adults aged 18 to 49, opening 21 million-strong US market
FDA expands Arexvy approval to at-risk adults 18-49, opening 21M-strong US market. Read what this means for GSK, Pfizer, Moderna, and the RSV vaccine landscape.
AptarGroup partners with Covirix Medical to explore inhalable antivirals for pandemic-potential respiratory viruses
AptarGroup, Inc. and Covirix Medical explore inhalable antivirals targeting pandemic respiratory viruses. Discover the strategy behind the partnership.
Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk
In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline’s Arexvy vaccine to…
EC approves Pfizer’s ABRYSVO RSV vaccine for infants and older adults
Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for ABRYSVO, its bivalent respiratory syncytial…
FDA greenlights Pfizer’s ABRYSVO vaccine for shielding infants from RSV
The US Food and Drug Administration (FDA) has granted approval to Pfizer Inc.’s ABRYSVO, a bivalent Respiratory Syncytial…
Pfizer RSVpreF vaccine candidate gets another FDA breakthrough therapy status
Pfizer said that PF-06928316 (RSVpreF), its respiratory syncytial virus (RSV) vaccine candidate, has been granted breakthrough therapy designation…
Pfizer gets FDA breakthrough status for RSVpreF RSV vaccine candidate
Pfizer has secured breakthrough therapy designation for its respiratory syncytial virus (RSV) vaccine candidate — PF-06928316 (RSVpreF) from…
Thermo Fisher Scientific to acquire Mesa Biotech for $500m to expand point-of-care diagnostics
Thermo Fisher Scientific, a global leader in laboratory and diagnostics solutions, has finalized an agreement to acquire Mesa…
Pfizer begins phase 3 clinical trials of 20vPnC, RSVpreF, and MenABCWY vaccine candidates
US pharma giant Pfizer has initiated four phase 3 clinical trials within its present pipeline of investigational vaccines.…